BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Beofenac® (aceclofenac): New contraindications and warnings

Active substance: aceclofenac

The company Almirall Hermal GmbH is circulating information that treatment with aceclofenac - similar to that with diclofenac and selective COX-2 inhibitors - is associated with an increased risk of arterial thrombotic events.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 1MB, File is accessible